hVIVO CEO, Kym Denny, interviewed by FierceBiotech on the SEEK joint venture, Imutex

May 18, 2016 3:59 pm

Nick Paul Taylor, writer with FierceBiotech, interviewed Kym Denny in late April 2016 , on the back of the joint venture announcement between hVIVO and SEEK Group to form Imutex.

Extracts from the published interview are below, and we provide a link to the full feature on the FierceBiotech website below.

‘SEEK Group and hVIVO (LON:HVO) have teamed up to create Imutex, a startup with a Phase IIa-ready universal flu vaccine and plans to advance a Zika virus shot into the clinic. The founding companies have invested £14 million ($20 million) and committed technology and resources to get Imutex off the ground.

“What we saw is a solid scientific hypothesis in regards to leveraging a T cell response that could have a multivirus approach,” hVIVO CEO Kym Denny told FierceBiotech. “We have a lot of experience in flu and conducting flu clinical trials, … [and] this led us to know that SEEK’s product is a really good candidate.”

A major test of this optimism is coming up. Imutex is working with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) to advance the vaccine candidate into a Phase IIa trial that will be run by the service wing of hVIVO. In parallel, Imutex is advancing a Zika virus vaccine into the clinic. “It’s very, very early stages, but obviously with the potential emergency fast-track designation it’s going to spend more time developing in humans rather than traditional preclinical testing,” Denny said. The plan is to start a first-in-human trial in collaboration with NIAID in the coming months.

For the full item on the FierceBiotech website please click here.

Comments are closed here.

Get in touch

Give us a call, or drop us an email. We'd love to hear from you!

Get in touch now